NCT00949624View on ClinicalTrials.gov

CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Advanced Solid Tumors
Interventions
DRUG

CP-868,596

Oral tablet 60 mg BID continuous

DRUG

Docetaxel

Intravenous 75 mg/m2 every three weeks

DRUG

CP-868,596

Oral tablet 100 mg BID continuous

DRUG

Docetaxel

Intravenous 75 mg/m2 every three weeks

DRUG

CP-868,596

Oral tablet 100 mg BID continuous

DRUG

Docetaxel

Intravenous 100 mg/m2 every three weeks

DRUG

CP-868,596

Oral tablet 60 mg BID continuous

DRUG

AG-013736

Oral tablet 5 mg BID continuous

DRUG

Docetaxel

Intravenous 75 mg/m2 every three weeks

Trial Locations (2)

3002

Pfizer Investigational Site, East Melbourne

27710

Pfizer Investigational Site, Durham

Sponsors
All Listed Sponsors
lead

Arog Pharmaceuticals, Inc.

INDUSTRY